Automate Your Wheel Strategy on TIL
With Tiblio's Option Bot, you can configure your own wheel strategy including TIL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TIL
- Rev/Share 0.0
- Book/Share 22.1827
- PB 1.0912
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC -0.7037
- MktCap 158783106.0
- FreeCF/Share -8.5258
- PFCF -2.8509
- PE -2.0264
- Debt/Assets 0.0
- DivYield 0
- ROE -0.4552
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | TIL | Jefferies | Hold | Buy | $11 | $52 | Jan. 7, 2025 |
News
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
TIL
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions
Read More
About Instil Bio, Inc. (TIL)
- IPO Date 2021-03-19
- Website https://instilbio.com
- Industry Biotechnology
- CEO Mr. Bronson Crouch
- Employees 14
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.